Update on PETRA trial investigating a next-generation PARP1 select inhibitor

TRESR trial: Investigating an ATRi in patients with DNA damage repair loss-of-function mutant tumorsПодробнее

PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutationsПодробнее

Clinical Trials Investigating PARP Inhibitors in Prostate CancerПодробнее

Overcoming resistance to PARP inhibition in ovarian cancerПодробнее

Use of PARP1-selective and ATR inhibitors to target DDR signalling pathwayПодробнее

PARP Inhibitor Trial UpdatesПодробнее

Evaluating future use of PARP inhibitors in neoadjuvant therapy for ovarian cancerПодробнее

Maximizing the potential of PARP inhibitors as first-line maintenance therapy in ovarian cancerПодробнее

The Role of Targeting DNA Repair Mutations in Advanced Prostate CancerПодробнее

Background of the KEYLYNK-007 trial for advanced solid tumoursПодробнее

Dr Timothy Yap Reiterates the Unmet Medical Need for Molecularly Targeted Agents in Solid TumorsПодробнее

How PARP inhibitors (PARPi) workПодробнее

Understanding the Side Effects of PARP InhibitorsПодробнее

Choosing the correct PARP inhibitor for prostate cancerПодробнее

Dr Timothy Yap: PARP/TOP1 Inhibitor Toxicities Can Be Managed Through Targeted DeliveryПодробнее

Learn About PARP Inhibitors For #ProstateCancer #Talzenna #AkeegaПодробнее

Update on PARP inhibitors in Ovarian and Pancreatic CancerПодробнее

Targeted cancer therapy: choosing the right assay to assess PARP inhibitorsПодробнее

PARP Inhibitors: 2023 UpdatesПодробнее